Document Detail


Acid and barriers. Current research and future developments for peptic ulcer therapy.
MedLine Citation:
PMID:  1978405     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Medical therapy for peptic ulcer disease has been targeted at inhibiting acid secretion based on the belief that ulcers occur due to an imbalance between aggressive and protective factors. New antisecretory agents are unlikely to show any dramatic improvement over the success and safety of histamine H2 receptor antagonists or the recently introduced H+K+ATPase proton pump antagonist omeprazole. The development of specific muscarinic M3 and gastrin receptor antagonists will provide useful agents to suppress acid and pepsinogen secretion by alternative means and may prevent the associated hypergastrinaemia seen with anti-secretory therapy. Enhancement of mucosal defence by site protective agents will be based on a better understanding of the vascular and immune factors involved in maintaining mucosal integrity and the growth factors that regulate wound healing. Molecular techniques are likely to produce the 'model anti-ulcer' agent which will effectively inhibit acid secretion and also enhance wound healing thus providing a cure for this chronic disease.
Authors:
J W Rademaker; R H Hunt
Related Documents :
2060595 - Gastric hyperacidity and mucosal damage caused by hypothermia correlate with increase i...
7828975 - Improved fold width and increased acid secretion after eradication of the organism in h...
3103205 - The role of mucus in the protection of the gastroduodenal mucosa.
5575235 - Spontaneous and persisting decrease in maximal acid output.
4613505 - Combinations of 4-aminobenzoic acid competitors and dihydrofolate dehydrogenase inhibit...
3445285 - A convenient synthesis of 3 beta,12 alpha-, 3 beta,7 alpha-, and 3 beta,7 beta-dihydrox...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Scandinavian journal of gastroenterology. Supplement     Volume:  175     ISSN:  0085-5928     ISO Abbreviation:  Scand. J. Gastroenterol. Suppl.     Publication Date:  1990  
Date Detail:
Created Date:  1990-12-05     Completed Date:  1990-12-05     Revised Date:  2008-02-13    
Medline Journal Info:
Nlm Unique ID:  0437034     Medline TA:  Scand J Gastroenterol Suppl     Country:  NORWAY    
Other Details:
Languages:  eng     Pagination:  19-26     Citation Subset:  IM    
Affiliation:
Division of Gastroenterology, McMaster University Medical Centre, Hamilton, Ontario, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antacids / therapeutic use*
Anti-Ulcer Agents / therapeutic use*
Gastric Mucosa / physiology
Helicobacter Infections / complications
Helicobacter pylori
Histamine H2 Antagonists / therapeutic use
Humans
Intestinal Mucosa / physiology
Peptic Ulcer / drug therapy*,  etiology
Wound Healing / physiology
Chemical
Reg. No./Substance:
0/Antacids; 0/Anti-Ulcer Agents; 0/Histamine H2 Antagonists

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Taking the tension out of the portal system. An approach to the management of portal hypertension in...
Next Document:  Inflammatory bowel disease revisited: newer drugs.